HUE031617T2 - Eljárás és készítmények élõ attenuált vírusokhoz - Google Patents

Eljárás és készítmények élõ attenuált vírusokhoz Download PDF

Info

Publication number
HUE031617T2
HUE031617T2 HUE08826570A HUE08826570A HUE031617T2 HU E031617 T2 HUE031617 T2 HU E031617T2 HU E08826570 A HUE08826570 A HU E08826570A HU E08826570 A HUE08826570 A HU E08826570A HU E031617 T2 HUE031617 T2 HU E031617T2
Authority
HU
Hungary
Prior art keywords
virus
live
kés
compositions
composition
Prior art date
Application number
HUE08826570A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jorge E Osorio
O'neil Wiggan
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39827288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE031617(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of HUE031617T2 publication Critical patent/HUE031617T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)

Claims (2)

  1. ® járás és kiÄÄykiAIÖ alteiiuáH vírttsekííox ÍZABMXáLy!:iGÉN:VIJON:röK. |:, Élő ÎiSsciâî.ïélï vkus készteétty, *| a következő kompiínensekeí tartidmttzea: :-«gy vagy több élő, atteaaàlt viras; egy vág)·' több pofetxtet t lg«- pohos: * propilén t'P.O-.PÓ} töt«« kopot íróén «hol as egy vagy több EO-PO tömb kopoíimer k&amp;eá tartozik a txdoxtgMz 40? {Plarauc 1-1:375¾ egy vagy több IVhène srer. ahol as egy vagy több túhárj«· s»«sr egy vagy több slbm»jns és egy vagy több sseohiJrài szén ahol &amp; egy vagy több szénhidrát szer kosé tartozik a néhaiba, éhé; ; k\. s/íí>«e«\ kv SOt svokkv nn ü az em ο»a 'V!-í t V mn í '«vhUí'aGí 2. g< ä x-x.vi, veeuah . n, Onvho, éhei « étö ..ítrontdt vaásóké? a Lv.eíkvéh cs'fortbó! v-s leset halj vtk ki Hass vous, íogavmts,, Coronavirus, HJhabo>.»vsrasv Piiovkns, iAff&amp;mysoAron Ortbsmysovkus, BéiiVtiVijsiS. Arertavrois, Retrovirus, Hepadnavirvt». Herpesvirus. Poxvirus csohldok, és ezek kombinadöí,
    1. As I -2. igénypontok hámdyike szerinti készítmény, aha) as éke «ftenuhk vírusok · '% Flavivirusok. 4, \t M !gvov|ívaa>k eOsne-kAo menais kosza mens, ahol a kevittnery .ara van adaptálva, boss Mgivöa, vagy teljesen dehidtatáíva legyen. á. As M. igénypontok bármelyik* saermb készlbodiy, ahol as egy vagy több album!« egy geïdi«ô#db|bd! Ä»Ä sasémnv albumin. $. As ΙΑ. igénypontok bármelyike >, seri ml készítmény, ahol az egy vagy több BÛ-PO tömb kopdinser pídoxamer -Pikk az egy vagy íöbb Tehene SKéntovtobiunm, és as egy vagy több szénhidrát vox ítubeiöz. ?, A 6. igCnypöot \eertnn kévzltmasn, «bol a pok>xameí· 40? {Píuro&amp;k MT74h) koaééntráclöja CktG FbkyitÉoí a szeram-albumln kmcmtinx lója (1,001-1 ν'*« év a «uhaláz koneeníráeiója 5 Ad v%.
  2. 8, Az I-? igénypontok bármely &amp;;« szerinti késeihnény, ahol az egy vagy több alhotnmtjp alábbi csöpoítbóí választ tűk kt. siarvasmarha szérotn-atboirurt és bontan .szerom-albumin 9, í ijaívo egy db atténuait vitae kesmménv inakî-vàkAàiVik gidkUoiP-e«', aezai 'UÍlomesve, hd|y egy vagy több élO abemsáb. víriist kombinálunk egy készítménnyel, amdy tartalmaz egy vagy több ;pídoxsetdéo-g>oiioa;ígfí)gílén t'bfJ>PO) íömb kopolimerti ahol as egy vagy több BO-Pü tömb fcopobtner közé iadb.dk a potoxamer 40? (Plútónk Π27Φ), egy vagy több Tehene szert) sbóisz eg,V vagy·' több feíiérie szer egy vagy több albumin: és egy vagy1 több szénhidrái «zert, ahol az egy vag>: több széithtdtúí: szer lehet behaíöz, atte! a készitn-vs·)' kerus baökkeraení az élő. attenttáh vitás itjakiîvâl^lb; fO A 9 sgáiVvpoat szartad eljárás, aszal j eile messe, hogy az éld, eöemtáíí vírttsakat a következő csoportból κι! as »halj eh kl: Fkmvksts, Togavtrtis, roronaviras, Pttsbdovitvss, Pilyvirus, PsáutayxoviröSi uríhiutív.vovirtís, Bunyovíros Arenactras, Ralrcvirns. Hepadttavtsus, ílerpesvíruv, Poxvtrus asatáílek, ás; ezek kösbbtoaeiók í ki A o ícOé'-p;«! etjXrás, a.sal sellenü-'sss Imgy t kev/an.et.v ítöseb i"\ vitás kcszátae.ty ts te .λ eV ; I . Gs ü y t at On et t-í ekn vagy ( k. v -etts Pus hOe t k éten tét! s, eg) ko'öot készárisényhez viszonyítva, Í|j:: A 9 ígénypom sí.etiab disais, asaui jelleítxíitve, b«gy « k&amp;ÄÄy «Äteml egy vises <·ίΑ, dienabll vîî'îk snakîivâJs&amp;ài -így vagy főbb lei&amp;£ys»ataádekdvxvdád etlíhntek egy kongd! kesatménylx;?/ viszoayitva, m íte : ÄÄ #y : ill, bbymíft y te-< ysaiiÄy ÉÂviW^ «Ä:S«$Äre| s s köveikévé ko;n;:»íK:«,«;ki·.: í8i!;Uaci;íX?»í le&amp;aîàhb egy tard a<!bny; es egy késKlbnenv, amely oude-v,.-' eg> xsgy dbb lebèsje kaerw ahol sa egy vagy több tehèrie sees egy vagy több aíbamln; egy vagy thfeh srérteürd >v«k agy vagy több s*éahlárótl s&amp;ítt, ahol &amp;&amp; egy vagy sbbh saénhddt ί,,-νν kbit irdudb?. vs vay vagy több yvb οχ le i be η pol kis ip; op i lén íbö-PO) kömh kopohmerb ahol s?. egy vagy több EÛ-PO tond; kopoHroer köve tartozik a polc-vaoisf 407 ! Plútódé F Ι27Φ>, es à Készítmény esOksentj egy eio atténuais vírus huskuva:a.'úf. 14 y i „Ü 1fèby|pÉiÉxt#i^lyte:8^itoô$késîiÉit»ïé^''.'*'^if' nl|B«':'^®àÂft-tbïteîiô' ilkabbbd&amp;'à. sunely csökkenti vagy sueudod egy egès/séd sllajxtl febeptét. • 5 A 14, igeoypûist uses ad djárás, a&amp;ws! jeUemm^·"^^'**9*«®«*»: csusxstbbl xilftuquk ki: nyugai-nite fc«6«l Oersgue 1¾¾ Japán atgyvcfôgyu»^ Murray \ .Ole) ttg) vdôgyuilstîâs Si L>xns ug>veiôgynliadto.
HUE08826570A 2007-04-06 2008-04-04 Eljárás és készítmények élõ attenuált vírusokhoz HUE031617T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91057907P 2007-04-06 2007-04-06

Publications (1)

Publication Number Publication Date
HUE031617T2 true HUE031617T2 (hu) 2017-07-28

Family

ID=39827288

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08826570A HUE031617T2 (hu) 2007-04-06 2008-04-04 Eljárás és készítmények élõ attenuált vírusokhoz

Country Status (28)

Country Link
US (4) US8084039B2 (hu)
EP (2) EP2940129B1 (hu)
JP (4) JP5296775B2 (hu)
KR (4) KR20150082667A (hu)
CN (4) CN104083757A (hu)
AU (1) AU2008279576C1 (hu)
BR (1) BRPI0809663B8 (hu)
CA (1) CA2720570C (hu)
CO (1) CO6260150A2 (hu)
CU (1) CU20090169A7 (hu)
CY (1) CY1118958T1 (hu)
DK (1) DK2144998T3 (hu)
ES (1) ES2621511T3 (hu)
HK (2) HK1140516A1 (hu)
HR (1) HRP20170513T1 (hu)
HU (1) HUE031617T2 (hu)
IL (3) IL201429A (hu)
LT (1) LT2144998T (hu)
MX (2) MX2009010798A (hu)
MY (2) MY180465A (hu)
NZ (2) NZ600958A (hu)
PH (1) PH12015500773B1 (hu)
PL (1) PL2144998T3 (hu)
PT (1) PT2144998T (hu)
SG (2) SG10201508397VA (hu)
SI (1) SI2144998T1 (hu)
WO (1) WO2009014774A1 (hu)
ZA (2) ZA200907790B (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY180465A (en) 2007-04-06 2020-11-30 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
BRPI0922788B8 (pt) * 2008-12-05 2021-05-25 Inviragen Inc composição para uso no crescimento de culturas virais e kit para cultura de vírus
EP2432455B1 (en) 2009-05-18 2014-11-12 Sigmoid Pharma Limited Composition comprising oil drops
CA2770570A1 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
RU2013143149A (ru) * 2011-02-24 2015-03-27 Пэксвэкс, Инк. Составы, пригодные для вакцин, получаемых сушкой распылением
EA201391515A1 (ru) * 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. Инактивированная вакцина вируса денге
CN108588035A (zh) * 2011-06-28 2018-09-28 白血球保健股份有限公司 病毒或细菌的新型稳定方法
CA2859916C (en) 2012-01-09 2021-02-09 Sanofi Pasteur Biologics, Llc Purification of herpes virus
US11260123B2 (en) 2012-05-21 2022-03-01 Sanofi Pasteur Limited Herpesvirus compositions and related methods
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3060247A1 (en) * 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN103877565A (zh) * 2014-02-24 2014-06-25 黄淮学院 治疗膀胱癌的基因针剂及其制备方法
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
AU2015362687B2 (en) * 2014-12-18 2021-12-09 Amgen Inc. Stable frozen herpes simplex virus formulation
EP3270960A4 (en) * 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
TWI569806B (zh) * 2015-06-10 2017-02-11 輔英科技大學 Stabilizer compositions for vaccines and methods for their preparation and swine fever vaccine containing the same
EP3355916A4 (en) * 2015-09-30 2018-08-29 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
BE1024160B9 (fr) * 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
AR107262A1 (es) * 2016-01-27 2018-04-11 Lilly Co Eli Inactivación de patógenos por delipidación
EP3418376B1 (en) * 2016-02-18 2024-03-13 Keio University Cell culture medium, culture method, and organoid
US11311487B2 (en) * 2016-04-14 2022-04-26 Trizell Ltd. Viral vector stabilization
CN105925541A (zh) * 2016-05-13 2016-09-07 云南省畜牧兽医科学院 一种蓝舌病病毒冻存保护剂及冻存方法
TW202309276A (zh) * 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
WO2018211419A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CN107475204A (zh) * 2017-08-03 2017-12-15 中国人民解放军军事医学科学院军事兽医研究所 一种囊膜病毒保护剂及其制备方法
CN107233576B (zh) * 2017-08-08 2020-02-07 江苏省农业科学院 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
KR20200083540A (ko) * 2017-11-01 2020-07-08 머크 샤프 앤드 돔 코포레이션 시토메갈로바이러스의 안정한 제형
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
JP7437385B2 (ja) * 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
US20220193222A1 (en) * 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
US20210322542A1 (en) * 2020-04-11 2021-10-21 Qiyi Xie Vaccination against coronavirus with poliomyelitis vaccine
WO2022037248A1 (en) * 2020-08-19 2022-02-24 Versitech Limited Live attenuated sars-cov-2 virus immunogenic compositions, methods of making and using
WO2024073860A1 (en) * 2022-10-07 2024-04-11 Elarex Inc. Stabilization of virus-based therapeutic agent

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
EP1005363B1 (en) * 1997-07-31 2006-03-29 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6163606A (en) * 1998-09-16 2000-12-19 Lucent Technologies Inc. System for providing virtual called party identification in a voice mail system
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
EA004131B1 (ru) 1999-05-04 2003-12-25 Энхайдро Лимитед Способ сохранения вирусов и микоплазмы
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
AT410634B (de) * 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CA2482448C (en) * 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
CN100335115C (zh) 2002-04-15 2007-09-05 山东哲夫 用于皮炎治疗的软膏
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US6873807B2 (en) * 2003-03-20 2005-03-29 Kabushiki Kaisha Toshiba Image forming apparatus
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7294455B2 (en) 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
JP2007516968A (ja) * 2003-12-05 2007-06-28 ベクトン・ディキンソン・アンド・カンパニー 皮内コンパートメントにおける免疫応答を増強する方法、およびそれらの方法で有用な化合物
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US20050276785A1 (en) * 2004-06-09 2005-12-15 Schering Aktiengesellschaft Treatment of cardiomyopathy and of endothelial dysfunction
EP1645283A1 (en) * 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
MY180465A (en) * 2007-04-06 2020-11-30 Takeda Vaccines Inc Methods and compositions for live attenuated viruses

Also Published As

Publication number Publication date
IL248522B (en) 2019-11-28
ES2621511T3 (es) 2017-07-04
BRPI0809663B1 (pt) 2020-02-11
KR20180036801A (ko) 2018-04-09
JP5296775B2 (ja) 2013-09-25
SG10201913741YA (en) 2020-03-30
US11197923B2 (en) 2021-12-14
KR101562971B1 (ko) 2015-10-23
PH12015500773A1 (en) 2017-08-07
IL201429A (en) 2013-09-30
CN104083757A (zh) 2014-10-08
AU2008279576C1 (en) 2014-01-23
EP2144998A1 (en) 2010-01-20
BRPI0809663A2 (pt) 2014-10-14
DK2144998T3 (en) 2017-04-10
HK1140516A1 (zh) 2010-10-15
HRP20170513T1 (hr) 2017-06-02
HK1217168A1 (zh) 2016-12-30
EP2144998B1 (en) 2017-01-04
SI2144998T1 (sl) 2017-05-31
JP2013209421A (ja) 2013-10-10
LT2144998T (lt) 2017-04-25
EP2940129A1 (en) 2015-11-04
MX360728B (es) 2018-11-14
PL2144998T3 (pl) 2017-07-31
KR20170038110A (ko) 2017-04-05
US20140302091A1 (en) 2014-10-09
MY180465A (en) 2020-11-30
ZA200907790B (en) 2014-04-30
PT2144998T (pt) 2017-04-07
CN101679954A (zh) 2010-03-24
JP6817370B2 (ja) 2021-01-20
KR20100016294A (ko) 2010-02-12
AU2008279576B2 (en) 2013-08-22
KR102134980B1 (ko) 2020-07-16
IL201429A0 (en) 2011-08-01
NZ580978A (en) 2012-07-27
CU20090169A7 (es) 2012-06-21
IL248522A0 (en) 2016-12-29
MX2009010798A (es) 2010-02-18
PH12015500773B1 (en) 2017-08-07
CA2720570A1 (en) 2009-01-29
NZ600958A (en) 2015-05-29
JP2016041753A (ja) 2016-03-31
JP2019172686A (ja) 2019-10-10
WO2009014774A1 (en) 2009-01-29
US20170100474A1 (en) 2017-04-13
AU2008279576A1 (en) 2009-01-29
CO6260150A2 (es) 2011-03-22
BRPI0809663B8 (pt) 2021-05-25
EP2144998A4 (en) 2011-11-02
IL228065B (en) 2019-05-30
EP2940129B1 (en) 2020-05-06
US10525120B2 (en) 2020-01-07
CN104998257A (zh) 2015-10-28
SG10201508397VA (en) 2015-11-27
ZA201400725B (en) 2022-11-30
CY1118958T1 (el) 2018-01-10
CN110478479A (zh) 2019-11-22
BRPI0809663A8 (pt) 2017-07-11
CA2720570C (en) 2022-10-04
KR20150082667A (ko) 2015-07-15
US20200108136A1 (en) 2020-04-09
US20080248551A1 (en) 2008-10-09
MY156422A (en) 2016-02-26
JP2010523127A (ja) 2010-07-15
US8084039B2 (en) 2011-12-27
IL228065A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
US11197923B2 (en) Methods and compositions for live attenuated viruses
US20190134182A1 (en) Compositions and methods for live, attenuated alphavirus formulations
AU2016213859B2 (en) Methods and compositions for live attenuated viruses
AU2013260732A1 (en) Methods and compositions for live attenuated viruses